Close
Close
Penta-Deca-Arginate (PDA), Tesamorelin, Ipamorelin Combo

Penta-Deca-Arginate (PDA), Tesamorelin, Ipamorelin Combo 3-Month Membership Program

$2,750.00

4.9 Avg. Rating

1000+ Reviews

  • Follow-up Exam
  • Lab Review
  • Dose Adjustments
  • Certificate of Authenticity
  • 503A Pharmacies
  • 99% Pure
  • US-based Peptides
This combination brings together three peptides that patients often ask about individually: Pentadeca Arginate (PDA), Tesamorelin, and Ipamorelin. Because each of these peptides works through a different pathway, some providers combine them with the goal of addressing recovery, body composition, and growth hormone support at the same time, as part of one coordinated plan.
PDA shares the same active sequence as BPC-157, a peptide studied for its potential role in tissue repair and gut health. Tesamorelin is a growth hormone-releasing hormone analog that actually carries FDA approval for a specific medical use, reducing excess abdominal fat in people with HIV-associated lipodystrophy, a condition involving abnormal fat distribution. Ipamorelin is a selective growth hormone secretagogue studied for its ability to prompt the release of growth hormone with a more targeted hormonal profile than some older compounds in its category.
Patients commonly ask about this combination because it brings together a tissue-repair-focused peptide with two peptides that work through the growth hormone pathway from different angles, one stimulating growth hormone release more broadly through the GHRH pathway (Tesamorelin) and one triggering a more selective pulse (Ipamorelin). The idea behind combining these three is to support several complementary goals, recovery, body composition, and growth hormone-related wellness, within one plan.
It’s important to understand that while each individual peptide has its own body of research, described in more detail on their dedicated pages, this specific three-peptide combination has not been studied together as a single protocol in dedicated human clinical trials. This page aims to give you an honest, combined picture based on what’s known about each component.
To understand this combination, it helps to think of it as addressing three different jobs at once. PDA is studied, through its shared identity with BPC-157, for its potential role in supporting blood flow and repair signaling in stressed or injured tissue, like a repair crew working on damaged infrastructure. Tesamorelin works by binding to receptors in the pituitary gland that respond to growth hormone-releasing hormone, prompting the pituitary to release growth hormone in a natural, pulsing pattern. This is part of why it has an FDA-approved role in reducing a specific type of abdominal fat associated with lipodystrophy, since growth hormone plays a role in fat metabolism. Ipamorelin works through a different pathway, mimicking a natural hormone signal related to ghrelin to trigger a more selective, targeted pulse of growth hormone release, with less effect on other hormones like cortisol and prolactin compared to older compounds in its category. When combined, the idea is that Tesamorelin and Ipamorelin work together on the growth hormone pathway from two different angles, one priming the system and one triggering the pulse, similar to how CJC-1295 and Ipamorelin are often paired, while PDA addresses tissue repair through an entirely separate mechanism. This is a reasonable combination in concept, but as with any multi-peptide protocol, the combined effect of all three together has not been directly studied in human research.
  • May help support tissue repair and recovery through PDA’s studied mechanisms, shared with BPC-157, related to blood flow and tissue signaling
  • May help support healthy body composition, particularly reduction of certain fat deposits, through Tesamorelin’s FDA-approved mechanism in a specific population, and its studied effects more broadly on growth hormone-related fat metabolism
  • May help promote growth hormone release through Ipamorelin’s more selective, targeted mechanism, working alongside Tesamorelin’s broader GHRH-pathway stimulation
  • Is currently being studied as a combined approach by some providers seeking to address recovery and growth hormone support together, though the three-peptide combination itself lacks dedicated research
Because this specific combination has not been studied together in human clinical trials, these potential benefits should be understood as a reasonable extension of each peptide’s individual, established research, rather than a proven combined effect.
Patients who commonly ask about this combination include those interested in:
  • Athletic recovery, particularly active adults looking for more comprehensive peptide-based support spanning tissue repair and growth hormone pathways
  • Body composition support, for patients interested in Tesamorelin’s studied effects on fat metabolism, particularly visceral fat
  • Healthy aging, for patients noticing age-related changes in recovery, body composition, and growth hormone levels
  • Wellness optimization, for patients working with a provider on a broader, multi-pathway recovery and vitality plan
This combination is not appropriate for everyone, and given the individual considerations for each component, along with the lack of direct research on the three-peptide combination itself, it requires a particularly thorough conversation with a licensed provider before starting.
Each peptide in this combination has its own research base. PDA’s research picture is identical to that of BPC-157, since they share the same active sequence: an extensive body of animal and laboratory research, with more limited human clinical trial data, as discussed in more detail on our dedicated PDA and BPC-157 pages. Tesamorelin has the most robust human clinical trial evidence of the three components, supported by Phase III trials that led to its FDA approval for reducing excess abdominal fat in HIV-associated lipodystrophy, with research showing meaningful reductions in visceral fat compared to placebo. Ipamorelin has been studied for its selective growth hormone-releasing profile, generally showing a more targeted effect on growth hormone with less impact on cortisol and prolactin compared to some older compounds, though large-scale, long-term outcome trials in generally healthy adults remain more limited. It’s important to be transparent that no dedicated clinical trials have examined this specific three-peptide combination together. The rationale for combining them is built by extrapolating from each peptide’s individual, separately studied mechanisms rather than from direct evidence of a combined effect. Additionally, PDA’s underlying peptide sequence does not have FDA approval and its regulatory status for compounding continues to be reviewed, which is an important factor to discuss with your provider alongside Tesamorelin’s more established, though narrowly approved, regulatory status.
Because this combination includes three peptides with different research and regulatory profiles, safety considerations should be reviewed individually for each component as well as together. Tesamorelin’s most commonly reported effects include joint discomfort, injection site reactions, pain in the extremities, swelling, and muscle aches, based on its FDA-approved clinical trial data. Ipamorelin’s reported effects are generally described as mild, including possible injection site reactions and headache. PDA’s shared sequence with BPC-157 has generally shown a mild side effect profile in available research, though comprehensive long-term human safety data remains more limited for this component. Because no dedicated research exists on the combined use of all three peptides together, this combination requires an especially thorough conversation with your provider, including a full review of your medical history. Patients with certain active health conditions may not be appropriate candidates for one or more components of this combination. This is not a complete list of contraindications, and only a licensed provider can help you understand whether this combination is a reasonable option to explore. Ongoing medical supervision, including regular follow-up and monitoring, is especially important with a multi-peptide combination like this one. Patients should follow their provider’s guidance closely and report any unexpected symptoms.

What does this combination do?

It brings together PDA for tissue repair support, Tesamorelin for growth hormone and fat metabolism support, and Ipamorelin for a more selective growth hormone pulse, addressing several goals within one plan.

Is this combination FDA-approved?

No, not as a combination. Tesamorelin individually carries FDA approval for a specific use in HIV-associated lipodystrophy, but PDA and Ipamorelin do not have FDA approval, and the three-peptide combination has not been studied together.

How long before I may notice changes?

This varies by individual and by which effects you’re focused on, and your provider can help set realistic expectations based on the individual research for each component.

Is it an injection?

Yes, all three peptides in this combination are typically administered as subcutaneous injections, often on individualized schedules determined by your provider.

Can it be combined with other peptides?

This combination already includes three peptides; adding others should only be considered with careful provider guidance given the number of pathways already involved.

Can it be combined with GLP-1 medications?

In some cases, yes. Your provider can help determine whether this fits your specific health goals and history.

Will I need lab work?

Yes. Given the number of pathways involved, baseline and follow-up lab testing is an important part of monitoring this combination safely and effectively.

Who should avoid this peptide?

Patients with certain active health conditions relevant to any of the three components may not be appropriate candidates. A full medical evaluation will help determine this.

How long do patients typically remain on therapy?

Treatment plans are individualized, but many programs are structured around a three-month cycle with a comprehensive follow-up to reassess progress and goals.

Is a consultation required?

Yes. A telehealth consultation with a licensed medical provider is required before starting this combination or any peptide therapy at SevenHealth.
Every peptide treatment program at SevenHealth is built around comprehensive, individualized medical care. When you begin therapy, your program includes:
  • An initial telehealth medical history and comprehensive evaluation with a licensed medical provider
  • Review of previous laboratory results when available, or recommendations for laboratory testing when medically appropriate
  • Personalized treatment recommendations based on your medical history and goals
  • Three months of prescribed peptide therapy when medically appropriate
  • A customized dosing and titration schedule specific to your prescribed peptides
  • A comprehensive follow-up appointment approximately three months after starting treatment
  • Review of progress, discussion of results, treatment adjustments if medically appropriate, and continued provider guidance
  • Ongoing provider oversight throughout your treatment program
  • No additional fees for appointments included within the treatment program
  • No additional fees for laboratory review as part of your treatment
Our goal is to make your experience with peptide therapy simple, transparent, and medically supervised from your very first consultation through every follow-up appointment. Given that this combination brings together three distinct peptides, your provider will place particular emphasis on coordinated monitoring and honest conversation about what each component is, and isn’t, expected to do.
Patients choose SevenHealth because we focus on individualized, medically supervised care rather than one-size-fits-all protocols. Every treatment plan is built around your specific health history and goals, and every prescription is overseen by a licensed medical provider from start to finish. We work with FDA-registered 503A U.S. compounding pharmacies that follow applicable quality standards, so you can feel confident in the source and handling of your prescribed peptide therapy, to the extent current regulations allow. Dosing is guided by your provider, not guesswork, and every program includes a three-month follow-up to review your progress and make adjustments if needed. We also believe in transparent pricing and honest education. There are no surprise appointment fees or lab review fees hidden within your treatment program, and we believe in giving patients a clear, accurate picture of where the science and regulatory landscape currently stand for each component of a combination like this one.
  • This combination brings together PDA (tissue repair), Tesamorelin (growth hormone and fat metabolism), and Ipamorelin (selective growth hormone release).
  • Tesamorelin carries FDA approval for a specific use in HIV-associated lipodystrophy; PDA and Ipamorelin do not have FDA approval.
  • No dedicated human research exists on this specific three-peptide combination used together.
  • Each peptide has its own individual research base, ranging from robust (Tesamorelin) to more limited (PDA, Ipamorelin).
  • Side effects should be reviewed individually for each component, and monitoring should reflect the combination as a whole.
  • This combination requires a particularly thorough conversation with your provider given its complexity.
  • SevenHealth includes an initial evaluation, personalized dosing, lab review, and a three-month follow-up in every treatment program.
  • Regulatory status for PDA continues to evolve and should be confirmed with your provider at the time of treatment.

Educational Disclaimer

This information is provided for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Peptide therapy should only be used under the supervision of a licensed healthcare provider after an appropriate medical evaluation. Individual results may vary.

$100 OFF GLP-1 Injectable Plans for New Members ! CODE: